Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Squamous Cell | 13 | 2016 | 1076 | 0.720 |
Why?
|
| Head and Neck Neoplasms | 14 | 2017 | 1052 | 0.660 |
Why?
|
| Tongue Diseases | 1 | 2016 | 8 | 0.580 |
Why?
|
| Ossification, Heterotopic | 1 | 2016 | 31 | 0.560 |
Why?
|
| Choristoma | 1 | 2016 | 68 | 0.550 |
Why?
|
| Mouth Neoplasms | 4 | 2010 | 194 | 0.400 |
Why?
|
| Oropharynx | 2 | 2016 | 15 | 0.290 |
Why?
|
| Laryngeal Neoplasms | 3 | 2017 | 89 | 0.280 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2011 | 1313 | 0.280 |
Why?
|
| Tumor Virus Infections | 2 | 2014 | 81 | 0.270 |
Why?
|
| Trachea | 2 | 2017 | 293 | 0.270 |
Why?
|
| Papillomaviridae | 2 | 2014 | 153 | 0.260 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2011 | 2438 | 0.250 |
Why?
|
| Chemoradiotherapy | 4 | 2017 | 301 | 0.230 |
Why?
|
| Photochemotherapy | 2 | 1995 | 97 | 0.230 |
Why?
|
| Larynx | 3 | 2017 | 38 | 0.230 |
Why?
|
| Papillomavirus Infections | 2 | 2014 | 239 | 0.220 |
Why?
|
| Genes, p53 | 4 | 1998 | 109 | 0.210 |
Why?
|
| Nasal Obstruction | 2 | 1997 | 21 | 0.190 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 1036 | 0.180 |
Why?
|
| Salvage Therapy | 1 | 2000 | 233 | 0.160 |
Why?
|
| Combined Modality Therapy | 10 | 2016 | 1686 | 0.160 |
Why?
|
| Adult | 21 | 2017 | 25648 | 0.160 |
Why?
|
| Tonsillar Neoplasms | 1 | 1997 | 6 | 0.160 |
Why?
|
| Glottis | 1 | 2017 | 11 | 0.150 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2016 | 173 | 0.150 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 1 | 2017 | 14 | 0.150 |
Why?
|
| Nasal Cavity | 1 | 1997 | 91 | 0.150 |
Why?
|
| Otolaryngology | 1 | 1997 | 53 | 0.140 |
Why?
|
| Punctures | 1 | 1996 | 29 | 0.140 |
Why?
|
| Carcinoma | 2 | 2016 | 436 | 0.140 |
Why?
|
| Tolonium Chloride | 1 | 1996 | 5 | 0.140 |
Why?
|
| Laryngeal Diseases | 2 | 2011 | 20 | 0.140 |
Why?
|
| Hypopharynx | 1 | 1996 | 8 | 0.140 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2016 | 47 | 0.140 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 1996 | 15 | 0.140 |
Why?
|
| Lymph Nodes | 4 | 2016 | 533 | 0.140 |
Why?
|
| Esophagus | 1 | 1996 | 102 | 0.140 |
Why?
|
| Respiration | 1 | 1997 | 262 | 0.140 |
Why?
|
| Female | 24 | 2017 | 44533 | 0.130 |
Why?
|
| Guideline Adherence | 1 | 2017 | 223 | 0.130 |
Why?
|
| Telangiectasia, Hereditary Hemorrhagic | 1 | 1994 | 15 | 0.130 |
Why?
|
| Neoplasm Staging | 7 | 2016 | 1939 | 0.120 |
Why?
|
| Humans | 34 | 2017 | 86644 | 0.120 |
Why?
|
| Epistaxis | 1 | 1994 | 19 | 0.120 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 1996 | 118 | 0.120 |
Why?
|
| Exercise | 1 | 1997 | 315 | 0.120 |
Why?
|
| Middle Aged | 20 | 2016 | 25028 | 0.120 |
Why?
|
| Nasal Mucosa | 1 | 1994 | 186 | 0.120 |
Why?
|
| Uterine Cervicitis | 1 | 1993 | 4 | 0.120 |
Why?
|
| Hydroxyurea | 7 | 2011 | 239 | 0.120 |
Why?
|
| Syncope | 1 | 1993 | 34 | 0.110 |
Why?
|
| Male | 24 | 2017 | 40966 | 0.110 |
Why?
|
| Follow-Up Studies | 8 | 2011 | 3640 | 0.110 |
Why?
|
| Prognosis | 8 | 2016 | 3679 | 0.110 |
Why?
|
| Fluorouracil | 7 | 2011 | 556 | 0.110 |
Why?
|
| Aged | 15 | 2016 | 18415 | 0.100 |
Why?
|
| Skin Neoplasms | 2 | 1995 | 546 | 0.100 |
Why?
|
| Vocal Cords | 1 | 2011 | 25 | 0.100 |
Why?
|
| Cumulative Trauma Disorders | 1 | 2011 | 18 | 0.100 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2011 | 66 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 3 | 2016 | 552 | 0.090 |
Why?
|
| Radiotherapy Dosage | 5 | 2011 | 468 | 0.090 |
Why?
|
| Airway Obstruction | 3 | 1999 | 109 | 0.080 |
Why?
|
| Genomics | 1 | 2014 | 720 | 0.080 |
Why?
|
| Neoplasms, Second Primary | 1 | 2011 | 252 | 0.080 |
Why?
|
| Disease-Free Survival | 5 | 2011 | 1204 | 0.080 |
Why?
|
| Laryngectomy | 2 | 2017 | 26 | 0.070 |
Why?
|
| Survival Rate | 5 | 2003 | 1863 | 0.070 |
Why?
|
| Paclitaxel | 5 | 2011 | 460 | 0.070 |
Why?
|
| Treatment Outcome | 8 | 2011 | 7993 | 0.070 |
Why?
|
| Neck Dissection | 1 | 2004 | 65 | 0.060 |
Why?
|
| Tongue Neoplasms | 2 | 2010 | 50 | 0.060 |
Why?
|
| Retrospective Studies | 7 | 2011 | 8489 | 0.060 |
Why?
|
| Remission Induction | 3 | 2016 | 722 | 0.060 |
Why?
|
| Induction Chemotherapy | 2 | 2016 | 147 | 0.050 |
Why?
|
| Alcohol Drinking | 2 | 2011 | 267 | 0.050 |
Why?
|
| Aged, 80 and over | 4 | 2011 | 6509 | 0.050 |
Why?
|
| Goiter, Nodular | 1 | 2001 | 6 | 0.050 |
Why?
|
| Mutation | 3 | 2014 | 3968 | 0.050 |
Why?
|
| Parathyroid Neoplasms | 1 | 2001 | 55 | 0.050 |
Why?
|
| Iodine Radioisotopes | 1 | 2001 | 134 | 0.050 |
Why?
|
| Survival Analysis | 3 | 2016 | 1538 | 0.050 |
Why?
|
| Smoking | 2 | 2011 | 609 | 0.050 |
Why?
|
| Evaluation Studies as Topic | 1 | 2000 | 274 | 0.040 |
Why?
|
| Crack Cocaine | 1 | 1999 | 3 | 0.040 |
Why?
|
| Adenoma | 1 | 2001 | 235 | 0.040 |
Why?
|
| Inhalation | 1 | 1999 | 31 | 0.040 |
Why?
|
| Registries | 2 | 2000 | 702 | 0.040 |
Why?
|
| Cocaine-Related Disorders | 1 | 1999 | 34 | 0.040 |
Why?
|
| Nebulizers and Vaporizers | 1 | 1999 | 55 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2011 | 4214 | 0.040 |
Why?
|
| Foreign Bodies | 1 | 1999 | 63 | 0.040 |
Why?
|
| Incidence | 3 | 2016 | 1577 | 0.040 |
Why?
|
| Cysts | 1 | 1999 | 104 | 0.040 |
Why?
|
| Airway Resistance | 1 | 1997 | 69 | 0.040 |
Why?
|
| Fluorometry | 1 | 1997 | 30 | 0.040 |
Why?
|
| Dilatation | 1 | 1997 | 48 | 0.040 |
Why?
|
| Pulmonary Edema | 1 | 1997 | 50 | 0.040 |
Why?
|
| Speech Disorders | 1 | 1996 | 18 | 0.040 |
Why?
|
| Speech Therapy | 1 | 1996 | 8 | 0.040 |
Why?
|
| Pharyngeal Neoplasms | 1 | 1996 | 15 | 0.040 |
Why?
|
| Pharynx | 1 | 1996 | 45 | 0.040 |
Why?
|
| Reference Values | 1 | 1997 | 674 | 0.030 |
Why?
|
| Everolimus | 1 | 2016 | 40 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 1997 | 912 | 0.030 |
Why?
|
| Sarcoma, Kaposi | 1 | 1995 | 19 | 0.030 |
Why?
|
| Heart Diseases | 1 | 1997 | 290 | 0.030 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 1994 | 16 | 0.030 |
Why?
|
| Human papillomavirus 18 | 1 | 2014 | 16 | 0.030 |
Why?
|
| United States | 2 | 2017 | 6672 | 0.030 |
Why?
|
| Human papillomavirus 16 | 1 | 2014 | 38 | 0.030 |
Why?
|
| Protein Interaction Maps | 1 | 2014 | 48 | 0.030 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 1993 | 19 | 0.030 |
Why?
|
| Cranial Nerves | 1 | 1993 | 6 | 0.030 |
Why?
|
| Photomicrography | 1 | 1993 | 7 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2004 | 176 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2017 | 572 | 0.030 |
Why?
|
| Multiple Myeloma | 1 | 2017 | 307 | 0.030 |
Why?
|
| Thyroid Neoplasms | 1 | 1998 | 408 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 171 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2014 | 2767 | 0.030 |
Why?
|
| Gene Expression | 1 | 1997 | 1284 | 0.030 |
Why?
|
| Photosensitizing Agents | 1 | 1993 | 48 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2016 | 2261 | 0.030 |
Why?
|
| Fibrosis | 1 | 1993 | 203 | 0.030 |
Why?
|
| Carotid Arteries | 1 | 1993 | 127 | 0.030 |
Why?
|
| Carboplatin | 2 | 2003 | 286 | 0.030 |
Why?
|
| Risk Factors | 2 | 2014 | 5417 | 0.030 |
Why?
|
| Surgical Flaps | 1 | 1994 | 241 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 582 | 0.030 |
Why?
|
| Organ Sparing Treatments | 1 | 2011 | 38 | 0.030 |
Why?
|
| Laser Therapy | 1 | 1993 | 142 | 0.030 |
Why?
|
| Recurrence | 1 | 1994 | 1139 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2011 | 35 | 0.030 |
Why?
|
| Retreatment | 1 | 2011 | 107 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 1993 | 381 | 0.020 |
Why?
|
| Pemetrexed | 1 | 2011 | 76 | 0.020 |
Why?
|
| Glutamates | 1 | 2011 | 89 | 0.020 |
Why?
|
| Quality of Life | 3 | 2003 | 1585 | 0.020 |
Why?
|
| Deglutition Disorders | 1 | 2011 | 115 | 0.020 |
Why?
|
| Guanine | 1 | 2011 | 208 | 0.020 |
Why?
|
| Osteoradionecrosis | 1 | 2010 | 18 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2011 | 237 | 0.020 |
Why?
|
| Deglutition | 1 | 2010 | 73 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2011 | 328 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 860 | 0.020 |
Why?
|
| Disease Progression | 2 | 2003 | 1531 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2014 | 1384 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 999 | 0.020 |
Why?
|
| Radiography | 2 | 1999 | 813 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 1999 | 3362 | 0.020 |
Why?
|
| Lymphatic Metastasis | 2 | 1998 | 486 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2004 | 159 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2014 | 3241 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 235 | 0.010 |
Why?
|
| Probability | 1 | 2004 | 355 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2004 | 292 | 0.010 |
Why?
|
| Erythropoietin | 1 | 2003 | 91 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2004 | 468 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 1998 | 1197 | 0.010 |
Why?
|
| Immunohistochemistry | 2 | 1998 | 1753 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 916 | 0.010 |
Why?
|
| Hyperthyroidism | 1 | 2001 | 75 | 0.010 |
Why?
|
| Parathyroidectomy | 1 | 2001 | 78 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 1014 | 0.010 |
Why?
|
| Thyroidectomy | 1 | 2001 | 170 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2001 | 429 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2004 | 1056 | 0.010 |
Why?
|
| Illinois | 1 | 2001 | 462 | 0.010 |
Why?
|
| Suppuration | 1 | 1999 | 9 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2001 | 684 | 0.010 |
Why?
|
| Laryngoscopy | 1 | 1999 | 44 | 0.010 |
Why?
|
| Tracheostomy | 1 | 1999 | 42 | 0.010 |
Why?
|
| Carcinoma, Papillary, Follicular | 1 | 1998 | 13 | 0.010 |
Why?
|
| Mouth Floor | 1 | 1997 | 4 | 0.010 |
Why?
|
| Capillaries | 1 | 1998 | 91 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 1998 | 158 | 0.010 |
Why?
|
| Paraffin Embedding | 1 | 1997 | 78 | 0.010 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 1998 | 51 | 0.010 |
Why?
|
| Microcirculation | 1 | 1997 | 106 | 0.010 |
Why?
|
| Mitosis | 1 | 1997 | 153 | 0.010 |
Why?
|
| Morbidity | 1 | 1997 | 148 | 0.010 |
Why?
|
| Carcinoma, Papillary | 1 | 1998 | 158 | 0.010 |
Why?
|
| Forecasting | 1 | 1997 | 304 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 1998 | 353 | 0.010 |
Why?
|
| Acute Disease | 1 | 1997 | 826 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 1997 | 579 | 0.010 |
Why?
|
| Ultrasonography | 1 | 1997 | 695 | 0.010 |
Why?
|
| Sex Factors | 1 | 1998 | 1054 | 0.010 |
Why?
|
| Respiration, Artificial | 1 | 1997 | 334 | 0.010 |
Why?
|
| Paraffin | 1 | 1993 | 4 | 0.010 |
Why?
|
| Chronic Disease | 1 | 1997 | 971 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 1993 | 165 | 0.010 |
Why?
|
| Age Factors | 1 | 1998 | 1851 | 0.010 |
Why?
|
| Hot Temperature | 1 | 1993 | 206 | 0.010 |
Why?
|
| Adolescent | 1 | 2004 | 8981 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 1997 | 1458 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 1998 | 1464 | 0.010 |
Why?
|